1-(3-Methylaminopropyl)-3-ethylcarbodiimide

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-(3-Methylaminopropyl)-3-ethylcarbodiimide
• 化学式: C₇H₁₅N₃
• 分子量: 141.21
• InChiKey: VIXIDUNQMRFCFO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  36.8
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF<br/>[FR] MODULATEURS D'ENZYMES DE MODIFICATION MÉTHYLIQUE, COMPOSITIONS ET UTILISATIONS ASSOCIÉES
  申请人：CONSTELLATION PHARMACEUTICALS INC

  公开号：WO2016130396A1

  公开（公告）日：2016-08-18

  Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with methyl modifying enzymes. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with methyl modifying enzymes.

  提供了式（I）的新化合物及其药学上可接受的盐，这些化合物对治疗与甲基修饰酶相关的各种疾病、疾病或症状有用。还提供了包含式（I）的新化合物、其药学上可接受的盐的药物组合物，以及治疗与甲基修饰酶相关的一种或多种疾病、疾病或症状的使用方法。
• [EN] BENZOTHIOPHENECARBOXAMIDE DERIVATIVES AND PGD2 ANTAGONISTS COMPRISING THEM<br/>[FR] DERIVES DU BENZOTHIOPHENECARBOXAMIDE, ET ANTAGONISTES DE LA PGD2 LES COMPRENANT
  申请人：SHIONOGI & CO., LTD.

  公开号：WO1998025919A1

  公开（公告）日：1998-06-18

  (EN) A compound, a pharmaceutically acceptable salt thereof, or a hydrate thereof having PGD2-antagonistic activities, inhibitory activities against infiltration of eosinophils, and being useful as a drug for treating diseases, such as systemic mastocytosis and disorder of systemic mast cell activation, as well as tracheal contraction, asthma, allergic rhinitis, allergic conjunctivitis, urticaria, ischemic reperfusion injury, inflammation and atopic dermatitis , which is shown by formula (I), is provided.(FR) L'invention porte sur un composé, un de ses sels pharmacocompatibles, ou un de ses hydrates, présentant des activités antagonistes vis-à-vis de la PGD2, des activités inhibitrices vis-à-vis des infiltrations d'éosinophiles, et s'avérant utiles comme médicaments pour le traitement de maladies telles que: la mastocytose systémique; les troubles de l'activation systémique des mastocytes; la contraction de la trachée; l'asthme; la rhinite allergique; la conjonctivite allergique; l'urticaire; les lésions ischémiques de reperfusion; et les dermatites inflammatoires et atopiques. Ledit composé est représenté par la formule (I).

  一种化合物，其药学上可接受的盐或水合物具有PGD2-拮抗活性、抑制嗜酸性粒细胞浸润的活性，并且可用作治疗疾病的药物，例如系统性肥大细胞增生症和系统性肥大细胞活化障碍，以及气道收缩、哮喘、过敏性鼻炎、过敏性结膜炎、荨麻疹、缺血再灌注损伤、炎症和特应性皮炎。该化合物由公式(I)表示。
• Methods for the treatment of itching comprising administering PGD2 receptor antagonists
  申请人：Shionogi & Co., Ltd.

  公开号：US20030027854A1

  公开（公告）日：2003-02-06

  A PGD 2 receptor antagonist such as a compound of the formula (IA-a-5): 1 a pharmaceutical acceptable salt thereof or a hydrate thereof, has an efficacious activity for the prevention or treatment of itching and is useful as a medicament.

  一种PGD2受体拮抗剂，例如公式（IA-a-5）的化合物：1a其医药上可接受的盐或其水合物，具有预防或治疗瘙痒的有效活性，并可用作药物。
• Size-controlled macromolecule
  申请人：Park Won Joon

  公开号：US20050037413A1

  公开（公告）日：2005-02-17

  The present application discloses a substrate that includes a molecular layer of regularly spaced size-controlled macromolecules comprising a polymer comprising branched and linear regions in which a plurality of termini on the branched region are bound to the substrate, and a terminus of the linear region is functionalized.

  本申请公开了一种基底，该基底包括由大小受控的大分子构成的分子层，所述大分子包括具有分支和线性区域的聚合物，在分支区域上的多个末端与基底结合，而线性区域的末端则被功能化。
• Pgd2 receptor antagonistic pharmaceutical compositions
  申请人：——

  公开号：US20040054003A1

  公开（公告）日：2004-03-18

  Compounds of the general formula (I) which are metabolically stable and have an antagonistic activity against PGD 2 receptor: 1 wherein Y is bicyclic ring; R 1 is optionally substituted heteroaryl; R 2 is hydrogen, etc.; R 3 is —CH 2 —CH 2 —CH 2 —CH 2 —CH═CH—COOR 4 , —CH 2 —CH 2 —CH 2 —CH 2 —X 1 —CH 2 —COOR 4 , —CH 2 —CH═CH—CH 2 —X 1 —CH 2 —COOR 4 or —CH 2 —CH 2 —CH 2 —CH 2 —COOR 4 ; R 4 is hydrogen, etc.; X 1 is —O—, etc.

  化合物的一般式(I)，其在代谢上稳定且对PGD2受体具有拮抗活性：其中，Y为双环环；R1为可选取代的杂环基；R2为氢等；R3为—CH2— — — —CH═CH—COOR4、— — — — —X1— —COOR4、— —CH═CH— —X1— —COOR4或— — — — —COOR4；R4为氢等；X1为—O—等。